National Practice Guideline Webinar Series
-
Register
- Non-Member - Free!
- Regular Member - Free!
- Retired - Free!
- Early Career Physician - Free!
- Resident - Free!
- Student - Free!
- Associate - Free!
- ASAM Staff - Free!
- International Member - Free!
- Emeritus Member - Free!
- Provisional Member - Free!
- Fellow Member - Free!
- Honorary Member - Free!
- CRT Member - Free!
The ASAM National Practice Guideline 2020 Webinar Series
Recorded: Tuesday, May 26, 2020 - Thursday, September 24, 2020
On-Demand Sessions
Session I: Fundamentals
Opioid use disorder is a chronic, relapsing disease, which has significant economic, personal, and public health consequences. The ASAM National Practice Guideline for the Use of Medications in the Treatment of Addiction Involving Opioid Use was developed to assist in the evaluation and treatment of opioid use disorder. Topics covered included: opioid withdrawal management, psycho-social treatment, special populations, and opioid overdose. The ASAM Guideline was the first guideline to address all medications available in the U.S. for the treatment of opioid addiction and overdose, in a single document. Since its publication in 2015, new medications and science in the field emerged, compelling ASAM to conduct a focused update.
The first of its series, this webinar outlines the highlights of the 2020 Focused Update of the National Practice Guideline for the Treatment of Opioid Use Disorder, focusing on the several new buprenorphine formulations recently approved by the FDA.
Session Information
Date: Tuesday, May 26, 2020
Speaker(s): Kyle Kampman, MD
Learning Objectives
By completing this session, you will be able to:
- 1. Summarize the guideline’s treatment recommendations and discuss how they should be used in practice.
- 2. Recognize the changing epidemiology of opioid use disorder and the remaining gaps in the treatments of OUD.
- 3. Describe the new buprenorphine formulations including generic and brand names, route of administration, dosing, and clinical considerations.
Session II: Pregnant Women
This session follows the ASAM National Practice Guideline 2020 Focused Update Fundamentals session, which outlines the new and updated recommendations in the 2020 Focused Update of the National Practice Guideline for the Treatment of Opioid Use Disorder.
Many of the risks associated with opioid use disorder are similar for both pregnant and non-pregnant women. However, opioid use disorder carries additional risks for pregnant women and prenatal risk for the developing fetus. Treatment of pregnant women with MOUD is associated with substantial improvement in outcomes for both mother and child. This session will provide an overview of the new and updated recommendations and in-depth information on treating pregnant women from the ASAM NPG.
Session Information
Date: Tuesday, June 30, 2020
Speaker(s): Tricia Wright, MD, MS, FACOG, FASAM
Learning Objectives
By completing this webinar, you will be able to:
- Summarize the guideline’s treatment recommendations for the mother-infant dyad and discuss their practical implications.
- Identify the fundamental components of an OUD patient assessment and diagnosis for pregnant and postpartum women.
- Recognize the unique needs and treatment recommendations for pregnant and postpartum women.
Session III: OUD and Pain
Acute and chronic pain is common in opioid use disorder. Pain is an important factor in non-adherence to treatment in Opioid Use Disorder (OUD). In the context of the current epidemic of nonmedical prescription drug use, knowledge of safe and effective pain management is critical for the practitioner. This webinar will provide an overview of the new and updated recommendations and in-depth information on treating pain in individuals with OUD from the ASAM National Practice Guideline.
Please Note: That recent legislation has removed the waiver requirement to prescribe buprenorphine. Some of the course content and descriptions refer to the waiver and we appreciate your patience as we work to update this content. To learn more about federal buprenorphine prescribing regulations, check out Policies Governing Buprenorphine for Opioid Use Disorder.
Session Information
Date: Tuesday, July 21, 2020
Speaker(s): Timothy Wiegand, MD, FACMT, FAACT, FASAM
Learning Objectives
By completing this webinar, you will be able to:
- Summarize the guideline’s treatment recommendations for individuals with pain & OUD & how they should be used in practice.
- Identify the fundamental components of an OUD patient assessment and diagnosis for individuals with pain.
- Recognize the unique needs and treatment recommendations for individuals with pain
Session IV: Individuals in the Criminal Justice System
A substantial proportion of persons in prisons, jails, drug courts, probation, parole, and who are criminally involved have opioid use disorder and related problems. The high concentration of at-risk individuals and conditions of incarceration can increase the risk of adverse consequences associated with drug use, including violence, medical and psychiatric co-morbidity, drug-related deaths, self-harm and suicide. Furthermore, treatment of OUD in CJ settings has all too often been sub-standard. For example, when individuals are released from incarceration without OUD treatment, they are at extreme risk of relapse overdose and death. This webinar will provide an overview of the new and updated recommendations and in-depth information on treating individuals in the criminal justice system from the ASAM National Practice Guideline.
Session Information
Date: Thursday, September 10, 2020
Speaker(s): Sandra Springer, MD
Learning Objectives
By completing this webinar, you will be able to:
- Summarize the guideline’s treatment recommendations for individuals in the criminal justice system with OUD and discuss how they should be used in practice.
- Identify the fundamental components of an OUD patient assessment and diagnosis for individuals in the criminal justice system.
- Recognize the unique needs and treatment recommendations for individuals in the criminal justice system
Session V: Adolescents & Young Adults
Adolescents and young adults present for treatment with a broad spectrum of opioid use disorder severity with a range of co-occurring medical and psychiatric illnesses. The treatment of youth with opioid use disorder presents many unique medical, legal, and ethical dilemmas that may complicate treatment. Given these unique issues, adolescents and young adults often benefit from services designed specifically for them. This webinar will provide an overview of the new and updated recommendations and in-depth information on treating youth with OUD from the ASAM National Practice Guideline.
Session Information
Date: Thursday, September 24, 2020
Speaker(s): Marc Fishman, MD
Learning Objectives
By completing this webinar, you will be able to:
- Summarize the guideline’s treatment recommendations for adolescents and young adults with OUD and discuss how they should be used in practice.
- Identify the fundamental components of an OUD patient assessment and diagnosis for adolescents and young adults.
- Recognize the unique needs and treatment recommendations for adolescents and young adults
Kyle M. Kampman
MD, FASAM
Kyle Kampman, MD, FASAM graduated from Northwestern University in 1981 and Tulane University School of Medicine in 1985. He interned at the National Naval Medical Center at Bethesda, Maryland, and served as a medical officer in the United States Navy from 1985 until 1990. He came to the University of Pennsylvania and served as a resident in Psychiatry from 1990 until 1993. He then completed a fellowship in Addiction Psychiatry. In 1994 he joined the faculty in the Department of Psychiatry as an assistant professor. He was promoted to associate professor in 2003 and to professor in 2012. Dr. Kampman has had extensive experience in the treatment of alcohol, cocaine, and opioid dependence. He chaired the committee that wrote the ASAM National Practice Guideline for the Use of Medications in the Treatment of Addiction Involving Opioid Use. He has conducted a number of trials testing medications for the treatment of cocaine, alcohol, and opioid dependence and is a recognized authority on the cocaine withdrawal syndrome. In addition to research, he works at the Addiction Recovery Unit of the Philadelphia VA Medical Center, where he continues to treat cocaine, alcohol, and opioid-dependent patients with both medications and psychotherapy.
No relevant financial relationships
Tricia E. Wright
MD MS FACOG DFASAM
| Tricia Wright, MD MS is an Associate Professor of Obstetrics, Gynecology and Women’s Health and Clinical Associate Professor of Psychiatry at the University of Hawai‘i John A. Burns School of Medicine and founder of the PATH Clinic, an outreach clinic of Waikiki Health, which provides perinatal and medical care to women with a history of substance use disorders. She is board certified in both Ob/Gyn and Addiction Medicine and a Fellow of the American College of Obstetrics and Gynecology and the American Society of Addiction Medicine. She has published multiple papers on pregnancy and addiction as well as a textbook Opioid Use Disorders in Pregnancy published in 2018 by Cambridge University Press. Dr. Wright completed her undergraduate degree in Biological Sciences from Stanford University, her MD from the University of Michigan. She completed her residency in Obstetrics and Gynecology from the University of New Mexico and obtained a Master’s Degree in Clinical Research from the University of Hawai‘i. |
Timothy J. Wiegand
MD, FACMT, FAACT, DFASAM
Timothy J. Wiegand, MD, FACMT, FAACT, DFASAM, specializes in Medical Toxicology and Addiction Medicine. He is an Associate Professor of Emergency Medicine and Director of the Toxicology/Addiction Consult Service at Strong Memorial Hospital and the University of Rochester Medical Center. He is Program Director for the URMC Addiction Medicine Fellowship Program, based out of the Department of Emergency Medicine and core faculty for their Emergency Medicine residency. Dr. Wiegand is also Medical Director for Huther Doyle, an addiction services provider in Rochester, New York.
In addition to ED, hospital, and clinic work treating intoxication, withdrawal, and assisting with pain management for patients maintained on Medications for Opioid Use Disorder Dr. Wiegand is involved with education and research in toxicology and addiction and he lectures locally, nationally, and internationally. Dr. Wiegand serves on the ASAM Board of Directors as Vice President; he is President of NYSAM and he is completing a second term on the Board of the American College of Medical Toxicology.
Dr. Wiegand serves in a volunteer capacity for many local, state, and national committees. He has been awarded the Charlotte Hegedus Award from the National Council on Alcoholism and Drug Dependence for professionals who have consistently demonstrated high level of cooperative work with individuals or groups with substance use disorders for at least five years. Dr. Wiegand is the 2022 awardee of the American Society of Addiction Medicine Annual Award. This award is given to an individual for outstanding contributions to the growth and vitality of ASAM, for thoughtful leadership in the field, and for a deep understanding of the art and science of Addiction Medicine.” And “for expanding the frontiers of the field of Addiction Medicine and broadening our understanding of the addictive process, through research and innovation.” He was also awarded the 2022 ACMT Service Award.
Sandra Springer
MD
Sandra Springer, MD is an Associate Professor of Medicine in the Department of Internal Medicine, Section of Infectious Diseases at the Yale School of Medicine. Dr. Springer is Board-Certified in Internal Medicine, Infectious Diseases, and Addiction Medicine. In addition, she is the Director of the Infectious Disease Clinic at the Newington site of the VA Connecticut Healthcare System, where she oversees the care of Veterans living with HIV (VLH). She graduated from Harvard University, then later received her Medical Degree from the University of Massachusetts Medical School. She did her Internal Medicine Residency and Infectious Disease Fellowship at Yale School of Medicine. Dr. Springer has significant clinical and research experience with persons living with HIV disease (PLH) and those with comorbid substance use disorders (SUD).
No relevant financial relationships
Marc Fishman
MD, DFASAM
Marc Fishman MD is a specialist in addiction psychiatry and addiction medicine. He is a member of the faculty of the Department of Psychiatry at the Johns Hopkins University School of Medicine. He leads Maryland Treatment Centers, which offers programs for residential and outpatient treatment of drug-involved and dual-diagnosis adolescents and adults. He has written and lectured widely on a variety of topics including youth treatment, placement and treatment matching strategies, co-occurring disorders, and medication treatment for addiction. His research focus has been in treatment of opioid use disorders in youth.
Dr. Fishman served as a co-editor for the most recent editions of ASAM's Patient Placement Criteria, leading the adolescent section, and served as the chief editor for the ASAM PPC Supplement on Pharmacotherapies for Alcohol Use Disorders. He is the chair of the Adolescent Committee for ASAM. He is a Past President of the Maryland Society of Addiction Medicine, and also a current member of the Board.
Disclosure Information
In accordance with disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all CME activities. These policies include resolving all possible conflicts of interest for the Planning Committees, CME Committee, MEC, and Faculty. All activity Planning Committee members and Faculty have disclosed relevant financial relationship information. The ASAM CME Committee has reviewed these disclosures and determined that the relationships are not inappropriate in the context of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.
- Kyle M. Kampman, MD – Does Disclose: World Meds (Clinical Condition: Opioid Use Disorder): Consultant/Advisory Board
- Tricia Wright, MD, MS, FACOG, FASAM - No relevant financial disclosures
- Timothy Wiegand, MD, FACMT, FAACT, FASAM - No relevant financial disclosures
- Sandra Springer, MD - No relevant financial disclosures
- Marc Fishman, MD - No relevant financial disclosures
Accreditation
This webinar series, recorded in 2020, is no longer eligible for CME/CE credits.
Key:
Complete
Next
Failed
Available
Locked